The Enterprise Value as of December 2025 (TTM) for Insight Molecular Diagnostics Inc. (0KCC.L) is 128.72M

According to Insight Molecular Diagnostics Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 128.72M. This represents a change of 2.59% compared to the average of 4.78M of the last 4 quarters.

Insight Molecular Diagnostics Inc. (0KCC.L) Historical Enterprise Value (quarterly & annually)

How has 0KCC.L Enterprise Value performed in the past?

The mean historical Enterprise Value of Insight Molecular Diagnostics Inc. over the last ten years is 96.09M. The current 128.72M Enterprise Value has changed 13.30% with respect to the historical average. Over the past ten years (40 quarters), 0KCC.L's Enterprise Value was at its highest in in the June 2021 quarter at 475.41M. The Enterprise Value was at its lowest in in the March 2025 quarter at -26764763.60.

Insight Molecular Diagnostics Inc. (0KCC.L) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Insight Molecular Diagnostics Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Insight Molecular Diagnostics Inc. (0KCC.L) Average Enterprise Value

How has 0KCC.L Enterprise Value performed in the past?

The current Enterprise Value of Insight Molecular Diagnostics Inc. (0KCC.L) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Insight Molecular Diagnostics Inc. (0KCC.L) Enterprise Value vs. Peers

How is 0KCC.L’s Enterprise Value compared to its peers?

Insight Molecular Diagnostics Inc.’s Enterprise Value is less than Sangamo Therapeutics, Inc. (136.78M), less than Heron Therapeutics, Inc. (377.39M), less than Codexis, Inc. (185.36M), less than Accuray Incorporated (238.50M), greater than Corbus Pharmaceuticals Holdings, Inc. (103.76M), less than Abeona Therapeutics Inc. (208.97M), less than Atara Biotherapeutics, Inc. (129.44M), less than Aclaris Therapeutics, Inc. (329.97M), less than Editas Medicine, Inc. (155.01M), greater than Adicet Bio, Inc. (22.28M),

Build a custom stock screener for Insight Molecular Diagnostics Inc. (0KCC.L) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Insight Molecular Diagnostics Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Insight Molecular Diagnostics Inc. (0KCC.L) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Insight Molecular Diagnostics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.